Subscribe to RSS
Download PDF
DOI: 10.1055/s-0033-1349428
Chronische Entzündung und AA-Amyloidose
Chronic inflammation and AA amyloidosisPublication History
23 April 2013
02 July 2013
Publication Date:
04 September 2013 (online)
Zusammenfassung
Die AA-Amyloidose ist eine schwerwiegende Folgeerkrankung bei chronischen entzündlichen Erkrankungen. Die Nierenbeteiligung steht im Vordergrund. Bei Patienten mit Risikofaktoren sollten regelmäßige Untersuchungen auf eine Mikroalbuminurie durchgeführt werden. Zur Therapie ist eine effektive Kontrolle der humoralen Entzündungsreaktion notwendig. Blutdruckeinstellung und andere nephroprotektive Maßnahmen tragen zum Erhalt der Nierenfunktion bei. Bei Progression der Amyloidose ist eine Nierenersatztherapie erforderlich; eine Nierentransplantation kann bei guter Kontrolle der Grunderkrankung durchgeführt werden.
Abstract
Systemic AA amyloidosis is a severe complication of chronic inflammatory diseases. Renal involvement is the predominant organ manifestation. Patients who are at risk for developing AA amyloidosis should be screened for microalbuminuria. The goal of therapy is an effective control of the acute phase reaction. A well controlled blood pressure and nephroprotective treatment contribute to the maintenance of renal function. In case of progressive amyloidosis dialysis is required. Renal transplantation can be performed if the underlying disease is well controlled.
-
Literatur
- 1 Aganna E, Hawkins PN, Ozen S et al. Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun 2004; 5: 289-293
- 2 Akpolat T, Özkaya O, Özen S. Homozygous M694V as a risk factor for amyloidosis in Turkish FMF patients. Gene 2012; 492: 285-289
- 3 Bellotti V, Chiti F. Amyloidogenesis in its biological environment: challenging a fundamental issue in protein misfolding diseases. Curr Opin Struct Biol 2008; 18: 771-779
- 4 Bergesio F, Ciciani AM, Manganaro M et al. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant 2008; 23: 941-951
- 5 Bodin K, Ellmerich S, Kahan MC et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010; 468: 93-97
- 6 Booth DR, Booth SE, Gillmore JD et al. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid 1998; 5: 262-265
- 7 Dember LM, Hawkins PN, Hazenberg BP et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007; 356: 2349-2360
- 8 Hazenberg BP, Bijzet J, Limburg PC et al. Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid 2007; 14: 133-140
- 9 Immonen K, Finne P, Hakala M et al. No improvement in survival of patients with amyloidosis associated with inflammatory rheumatic diseases -- data from the Finnish national registry for kidney diseases. J Rheumatol 2008; 35: 1334-1338
- 10 Koivuniemi R, Paimela L, Suomalainen R et al. Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid 2008; 15: 262-268
- 11 Lachmann HJ, Goodman HJ, Gilbertson JA et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361-2371
- 12 Linke RP, Oos R, Wiegel NM et al. Classification of amyloidosis: misdiagnosing by way of incomplete immunohistochemistry and how to prevent it. Acta Histochem 2006; 108: 197-208
- 13 Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583-596
- 14 Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011; 29: 1924-1933
- 15 Nakamura T, Higashi S, Tomoda K et al. Effectiveness of etanercept vs cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Rheumatology 2012; 51: 2064-2069
- 16 Obici L, Merlini G. AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly 2012; 142: w13580
- 17 Okuda Y, Yamada T, Matsuura M et al. Ageing: a risk factor for amyloid A amyloidosis in rheumatoid arthritis. Amyloid 2011; 18: 108-111
- 18 Okuda Y, Ohnishi M, Matoba K et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol 2013; Mar 5. [Epub ahead of print].
- 19 Schönland SO, Hegenbart U, Bochtler T et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 2012; 119: 488-493
- 20 Sipe JD, Benson MD, Buxbaum JN et al. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012; 19: 167-170
- 21 Sponarova J, Nyström SN, Westermark GT. AA-amyloidosis can be transferred by peripheral blood monocytes. PLoS One 2008; 3: e3308
- 22 Stankovic Stojanovic K, Delmas Y, Torres PU et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant 2012; 27: 1898-1901
- 23 Stix B, Kähne T, Sletten K et al. Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1, -2, and -3. Am J Pathol 2001; 159: 561-570
- 24 Tishko AN, Lapin SV, Vavilova TV et al. Early diagnostics of kidney damage in longstanding rheumatoid arthritis and amyloidosis. Amyloid 2011; 18 S1: 217-218
- 25 Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999; 265: 501-523
- 26 van Gameren II, Hazenberg BP, Bijzet J et al. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 2006; 54: 2015-2021
- 27 van der Hilst JC. Recent insights into the pathogenesis of type AA amyloidosis. Scientific World Journal 2011; 11: 641-650
- 28 Westermark P, Stenkvist B. A new method for the diagnosis of systemic amyloidosis. Arch Intern Med 1973; 132: 522-523